Columbia Laboratories (CBRX) 7.36 $CBRX
Viramal Appoints Women's Healthcare Expert, William Bologna, as Chairman of the Board of Directors
BusinessWire - Tue Feb 02, 7:30AM CST
Viramal, ("the Company"
, an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women's health, today announced the appointment of William Bologna as Chairman of the Board of Directors, effective immediately. Mr. Bologna is also the Company's chief scientist.
CBRX: 7.36 (+0.45)
Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)
PR Newswire - Mon Apr 13, 6:00AM CDT
Effective this morning, Columbia Laboratories, Inc. is now Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company" , and its Nottingham, UK based subsidiary Molecular Profiles, Ltd., is now Juniper Pharma Services. The Company's common stock will begin trading today under the symbol JNP on the Nasdaq Stock Exchange.
JNP: 6.91 (-0.06), CBRX: 7.36 (+0.45)
Columbia Laboratories announces new brand name & new trading symbol
M2 - Fri Apr 03, 3:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Thursday that it will adopt its new corporate brand name of Juniper Pharmaceuticals with effect from 10 April 2015.
CBRX: 7.36 (+0.45)
Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.
PR Newswire - Thu Apr 02, 6:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) (the "Company" , today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol -- "JNP" -- on Monday, April 13, 2015. The Company will also unveil its new logo and launch its new website, www.juniperpharma.com, on April 13, 2015.
CBRX: 7.36 (+0.45)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 16.48 (-1.52), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 73.95 (-0.48), ABBV: 61.00 (+0.25), CBRX: 7.36 (+0.45), ATRS: 1.05 (-0.04)
Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology
PR Newswire - Mon Mar 30, 7:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring ("IVR" technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring.
CBRX: 7.36 (+0.45)
Columbia Laboratories Shares Up 5.7% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Mar 23, 11:28AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 1 month, Columbia Laboratories has returned 5.68% as of today's recent price of $6.36.
CBRX: 7.36 (+0.45)
Columbia Laboratories posts lower net income of USD3.4m for 2014
M2 - Thu Mar 19, 6:35AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Wednesday that its net income was USD3.4m (USD0.27 per diluted share) for the 12-month period ended 31 December 2014.
CBRX: 7.36 (+0.45)
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 18, 1:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
VUZI: 5.80 (-0.03), ADXS: 8.56 (-0.26), ASPS: 26.64 (-1.72), VTAE: 10.19 (+0.07), HCCI: 12.20 (-0.26), AIRT: 23.75 (-0.50), CBRX: 7.36 (+0.45), TESO: 6.78 (-0.26), BOOM: 9.97 (-1.41), AVID: 5.91 (-0.14), ALOT: 15.24 (+0.06), RTRX: 17.40 (-0.30), TUES: 6.70 (-0.18), FPRX: 42.87 (+0.69), KPTI: 8.53 (-0.60)
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results
PR Newswire - Wed Mar 18, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or the "Company" , today announced financial results for the three- and twelve-month periods ended December 31, 2014.
CBRX: 7.36 (+0.45)
Uptrend Call Working As Columbia Laboratories Stock Rises 34.8% (CBRX)
Comtex SmarTrend(R) - Mon Mar 16, 11:27AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 3 weeks, Columbia Laboratories has returned 34.83% as of today's recent price of $8.11.
CBRX: 7.36 (+0.45)
Federal Appeals Court Affirms Dismissal of Class Action Lawsuit
PR Newswire - Thu Mar 12, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, announced today that the United States Court of Appeals for the Third Circuit affirmed the prior decision of the United States District Court for the District of New Jersey dismissing the securities class action lawsuit, entitled In re Columbia Laboratories, Inc., Securities Litigation, (D.C. No. 2-12-cv-00614) filed against Columbia, Watson Pharmaceuticals, Inc ("Watson" , and various Columbia and Watson executives.
CBRX: 7.36 (+0.45)
Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th Conference Call
PR Newswire - Tue Mar 10, 3:44PM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 18, 2015, to discuss financial results for the fourth quarter and full year ended December 31, 2014. The call details are as follows:
CBRX: 7.36 (+0.45)
Uptrend Call Working As Columbia Laboratories Stock Rises 23.7% (CBRX)
Comtex SmarTrend(R) - Mon Mar 09, 9:57AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 2 weeks, Columbia Laboratories has returned 23.69% as of today's recent price of $7.44.
CBRX: 7.36 (+0.45)
Viramal Appoints Women's Healthcare Expert, William Bologna, as Chairman of the Board of Directors
BusinessWire - Tue Feb 02, 7:30AM CST
Viramal, ("the Company"
, an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women's health, today announced the appointment of William Bologna as Chairman of the Board of Directors, effective immediately. Mr. Bologna is also the Company's chief scientist. CBRX: 7.36 (+0.45)
Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)
PR Newswire - Mon Apr 13, 6:00AM CDT
Effective this morning, Columbia Laboratories, Inc. is now Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"
, and its Nottingham, UK based subsidiary Molecular Profiles, Ltd., is now Juniper Pharma Services. The Company's common stock will begin trading today under the symbol JNP on the Nasdaq Stock Exchange. JNP: 6.91 (-0.06), CBRX: 7.36 (+0.45)
Columbia Laboratories announces new brand name & new trading symbol
M2 - Fri Apr 03, 3:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Thursday that it will adopt its new corporate brand name of Juniper Pharmaceuticals with effect from 10 April 2015.
CBRX: 7.36 (+0.45)
Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.
PR Newswire - Thu Apr 02, 6:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) (the "Company"
, today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol -- "JNP" -- on Monday, April 13, 2015. The Company will also unveil its new logo and launch its new website, www.juniperpharma.com, on April 13, 2015. CBRX: 7.36 (+0.45)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 16.48 (-1.52), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 73.95 (-0.48), ABBV: 61.00 (+0.25), CBRX: 7.36 (+0.45), ATRS: 1.05 (-0.04)
Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology
PR Newswire - Mon Mar 30, 7:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring ("IVR" technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring. CBRX: 7.36 (+0.45)
Columbia Laboratories Shares Up 5.7% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Mar 23, 11:28AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 1 month, Columbia Laboratories has returned 5.68% as of today's recent price of $6.36.
CBRX: 7.36 (+0.45)
Columbia Laboratories posts lower net income of USD3.4m for 2014
M2 - Thu Mar 19, 6:35AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Wednesday that its net income was USD3.4m (USD0.27 per diluted share) for the 12-month period ended 31 December 2014.
CBRX: 7.36 (+0.45)
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 18, 1:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
VUZI: 5.80 (-0.03), ADXS: 8.56 (-0.26), ASPS: 26.64 (-1.72), VTAE: 10.19 (+0.07), HCCI: 12.20 (-0.26), AIRT: 23.75 (-0.50), CBRX: 7.36 (+0.45), TESO: 6.78 (-0.26), BOOM: 9.97 (-1.41), AVID: 5.91 (-0.14), ALOT: 15.24 (+0.06), RTRX: 17.40 (-0.30), TUES: 6.70 (-0.18), FPRX: 42.87 (+0.69), KPTI: 8.53 (-0.60)
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results
PR Newswire - Wed Mar 18, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or the "Company"
, today announced financial results for the three- and twelve-month periods ended December 31, 2014. CBRX: 7.36 (+0.45)
Uptrend Call Working As Columbia Laboratories Stock Rises 34.8% (CBRX)
Comtex SmarTrend(R) - Mon Mar 16, 11:27AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 3 weeks, Columbia Laboratories has returned 34.83% as of today's recent price of $8.11.
CBRX: 7.36 (+0.45)
Federal Appeals Court Affirms Dismissal of Class Action Lawsuit
PR Newswire - Thu Mar 12, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, announced today that the United States Court of Appeals for the Third Circuit affirmed the prior decision of the United States District Court for the District of New Jersey dismissing the securities class action lawsuit, entitled In re Columbia Laboratories, Inc., Securities Litigation, (D.C. No. 2-12-cv-00614) filed against Columbia, Watson Pharmaceuticals, Inc ("Watson" , and various Columbia and Watson executives. CBRX: 7.36 (+0.45)
Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th Conference Call
PR Newswire - Tue Mar 10, 3:44PM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 18, 2015, to discuss financial results for the fourth quarter and full year ended December 31, 2014. The call details are as follows:
CBRX: 7.36 (+0.45)
Uptrend Call Working As Columbia Laboratories Stock Rises 23.7% (CBRX)
Comtex SmarTrend(R) - Mon Mar 09, 9:57AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 2 weeks, Columbia Laboratories has returned 23.69% as of today's recent price of $7.44.
CBRX: 7.36 (+0.45)
